Yuhei Miyanohana

This inventor holds 19 USPTO granted patents and 11 published patent applications and 11 EPO patents, primarily in Heterocyclic Compounds. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2019-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yuhei Miyanohana. Retrieved from https://idiyas.com/inventor/yuhei-miyanohana

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 (Patent Applications = 11)

% Patents Active = 100.0

EPO Patents = 11 (Patent Applications = 17)

Average Co-Inventor Count = 12.2

ph-index = 4

Forward Citations = 69(Granted Patents)

Company Filing History:

19 out of 1,226

Takeda Pharmaceutical Company Limited

patents

Years Active: 2019-2026

Loading Chart...

Areas of Expertise:

Heterocyclic Compound

Pyrrolidine Derivatives

Orexin Receptor Agonists

Excessive Sleepiness

Cataplexy Treatment

Sulfonamide Derivatives

Pharmaceutical Applications

Substituted Compounds

Medicinal Chemistry

Kanagawa, JP

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12662453 - Heterocyclic compound and use thereof (2026-06-23),

2. 12534471 - Pyrrolo[1, 2-c]imidazole derivatives as orexin type 2 receptor agonists and methods of use thereof (2026-01-27),

3. 12448377 - Heterocyclic compound (2025-10-21),

4. 12421188 - Heterocyclic compound and use thereof (2025-09-23),

5. 12415782 - Heterocyclic compound and use thereof (2025-09-16),

6. 12404237 - Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1'-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives (2025-09-02),

7. 12091410 - Heterocyclic compound (2024-09-17),

8. 12077522 - Heterocyclic compound and application thereof (2024-09-03),

9. 12071434 - Heterocyclic compound (2024-08-27),

10. 11987586 - Pyrrolo[1,2-c]imidazole derivatives as orexin type 2 receptor agonists (2024-05-21),

11. 11655241 - Heterocyclic compound and use thereof (2023-05-23),

12. 11440883 - Heterocyclic compound and use thereof (2022-09-13),

13. 11319286 - Heterocyclic compound and application thereof (2022-05-03),

14. 11059780 - Substituted pyrrolidine compound and use thereof (2021-07-13),

15. 11034700 - Substituted pyrrolidine compound and use thereof (2021-06-15),

Title: **Yuhei Miyanohana: Innovator in Heterocyclic Compounds**

Introduction

Yuhei Miyanohana is a notable inventor based in Kanagawa, Japan, renowned for his contributions to the field of medicinal chemistry. With a remarkable portfolio of 13 patents, Miyanohana is committed to advancing pharmaceutical innovations.

Latest Patents

Among his most recent inventions, Miyanohana has developed a heterocyclic compound that exhibits orexin type 2 receptor agonist activity. This innovation is significant for its potential application in the prevention and treatment of narcolepsy. The specific compound is represented by a unique formula, where each symbol has specific definitions provided in the detailed description. Additionally, he has another patent focused on the application of this heterocyclic compound, reiterating its relevance in treating narcolepsy through orexin type 2 receptor modulation.

Career Highlights

Miyanohana currently works at Takeda Pharmaceutical Company Limited, a leading global research and development-based pharmaceutical company. His role has enabled him to spearhead innovative projects that aim to improve health outcomes through groundbreaking therapies.

Collaborations

Throughout his career, Yuhei Miyanohana has collaborated with esteemed colleagues such as Tatsuki Koike and Yuichi Kajita. These partnerships have fostered a creative environment that emphasizes the importance of teamwork in the quest for new medical solutions.

Conclusion

Yuhei Miyanohana's dedication to innovation in the pharmaceutical field is exemplified through his extensive patent portfolio. His work not only showcases his expertise in heterocyclic compounds but also highlights the potential impacts of his inventions on treating neurological conditions like narcolepsy. As he continues his efforts at Takeda Pharmaceutical Company Limited, the future looks promising for further breakthroughs in medicine.

Profile summary based on public USPTO records.